Phase-2 Trial of palbociclib in adult patients with recurrent RB1-positive Glioblastoma

INTRODUCTION: Alterations in the CDK4/6 – RB signaling pathway are common causes of cell cycle dysregulation in many cancers, including glioblastoma. Palbociclib is an oral inhibitor of CDK4/6, which leads to phosphorylation of RB1 and cell-cycle arrest. We conducted a two-arm study evaluating effic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Neurooncol
Autors principals: Taylor, Jennie W., Parikh, Mili, Phillips, Joanna J., James, C. David, Molinaro, Annette M., Butowski, Nicholas A., Clarke, Jennifer L., Oberheim-Bush, Nancy Ann, Chang, Susan M., Berger, Mitchel S., Prados, Michael
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6239922/
https://ncbi.nlm.nih.gov/pubmed/30151703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-018-2977-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars